Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR Atyr PHARMA	$5.42 +1.4%	$3.44	$1.42 ▼ $5.75	$484.63M	0.88	1.00 million shs	1.95 million shs
CDTX Cidara Therapeutics	$25.16 +4.6%	$20.89	$10.14 ▼ $28.42	$315.73M	0.86	142,063 shs	147,459 shs
ITOS iTeos Therapeutics	$10.16 -0.2%	$7.29	$4.80 ▼ $18.13	$388.90M	1.39	655,949 shs	886,466 shs
NTGN Neon Therapeutics	$3.07	$3.03	$0.88 ▼ $6.25	$88.93M	-0.81	516,108 shs	N/A

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR Atyr PHARMA	+4.09%	+25.59%	+65.63%	+57.35%	+534,999,900.00%
CDTX Cidara Therapeutics	0.00%	+9.22%	+22.14%	+1.65%	+92.40%
ITOS iTeos Therapeutics	-0.20%	+1.50%	+53.15%	+44.40%	-41.49%
NTGN Neon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR Atyr PHARMA	2.7477 of 5 stars	3.6	1.0	0.0	0.0	3.1	3.3	0.6
CDTX Cidara Therapeutics	4.4033 of 5 stars	4.6	3.0	0.0	4.6	2.6	0.8	0.0
ITOS iTeos Therapeutics	3.3381 of 5 stars	4.1	2.0	0.0	0.0	2.8	3.3	0.6
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR Atyr PHARMA	3.14	Buy	$18.60	242.92% Upside
CDTX Cidara Therapeutics	3.22	Buy	$42.00	66.91% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	56.06% Upside
NTGN Neon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NTGN, ATYR, ITOS, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/4/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
6/2/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/27/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/23/2025	CDTX Cidara Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/19/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00

(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR Atyr PHARMA	$235K	2,054.29	N/A	N/A	$1.54 per share	3.52
CDTX Cidara Therapeutics	$302K	1,045.47	N/A	N/A	($1.82) per share	-13.83
ITOS iTeos Therapeutics	$35M	11.11	N/A	N/A	$16.08 per share	0.63
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	$0.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR Atyr PHARMA	-$50.39M	-$0.81	N/A	N/A	N/A	N/A	-79.44%	-59.16%	8/12/2025 (Estimated)
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	8/12/2025 (Estimated)
ITOS iTeos Therapeutics	-$112.64M	-$3.04	N/A	N/A	N/A	N/A	-20.11%	-17.50%	8/14/2025 (Estimated)
NTGN Neon Therapeutics	-$79.78M	-$2.86	N/A	N/A	N/A	N/A	-199.09%	-137.14%	N/A

Latest NTGN, ATYR, ITOS, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/7/2025	Q1 2025	ATYR Atyr PHARMA	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A
3/13/2025	Q4 2024	ATYR Atyr PHARMA	-$0.23	-$0.18	+$0.05	-$0.18	$0.02 million	N/A
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR Atyr PHARMA	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR Atyr PHARMA	0.02	5.41	5.41
CDTX Cidara Therapeutics	N/A	3.54	3.54
ITOS iTeos Therapeutics	N/A	14.80	14.80
NTGN Neon Therapeutics	0.43	1.58	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR Atyr PHARMA	61.72%
CDTX Cidara Therapeutics	35.82%
ITOS iTeos Therapeutics	97.16%
NTGN Neon Therapeutics	54.71%

Insider Ownership

Company	Insider Ownership
ATYR Atyr PHARMA	3.70%
CDTX Cidara Therapeutics	3.89%
ITOS iTeos Therapeutics	12.50%
NTGN Neon Therapeutics	38.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR Atyr PHARMA	53	89.00 million	80.84 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
ITOS iTeos Therapeutics	90	38.27 million	31.97 million	Optionable
NTGN Neon Therapeutics	102	28.97 million	N/A	Not Optionable

NTGN, ATYR, ITOS, and CDTX Headlines

Recent News About These Companies

Neon Gold Records, Avenue A unite to launch Futures Music Group

October 24, 2024 | musicbusinessworldwide.com

BioNTech grows in cell therapies, buying Kite's TCR platform

September 1, 2024 | pharmaphorum.com

Neon Trap Defense

April 14, 2024 | kotaku.com

BCYC Bicycle Therapeutics plc

April 9, 2024 | seekingalpha.com

neon oscillator

March 20, 2024 | hackaday.com

NTGN_old Historical Data

February 20, 2024 | investing.com

2000 Plymouth Neon

January 13, 2024 | cars.com

NBCO Neon Bloom, Inc.

December 22, 2023 | seekingalpha.com

Kansas City Ferris wheel could be out-dazzled by what will soon lie below: Neon Alley

November 13, 2023 | kansascity.com

Starfield Neon shops and locations – every vendor in Neon

November 4, 2023 | videogamer.com

A Nixie Clock With Neon Bulb Logic

October 5, 2023 | hackaday.com

Starfield | Where To Get Neon (Ne)

September 29, 2023 | hardcoregamer.com

Starfield Neon City guide – everything you need to know

September 14, 2023 | videogamer.com

Starfield: All Shops in Neon City

September 10, 2023 | twinfinite.net

Shadows in Neon

September 9, 2023 | ign.com

Starfield Neon city guide

August 19, 2023 | pcgamesn.com

Apex Legends Neon Network Collection Event

August 4, 2023 | ign.com

Fab Five: Neon fashion finds to brighten up your summer wardrobe

August 1, 2023 | vancouversun.com

Neon White physical edition for PS5, Switch launches September 15

July 21, 2023 | gematsu.com

Fast-paced platformer 'Neon White' is coming to Xbox

June 22, 2023 | engadget.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTGN, ATYR, ITOS, and CDTX Company Descriptions

Atyr PHARMA NASDAQ:ATYR

$5.42 +0.07 (+1.38%)

As of 03:55 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Cidara Therapeutics NASDAQ:CDTX

$25.16 +1.11 (+4.63%)

As of 03:55 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

iTeos Therapeutics NASDAQ:ITOS

$10.16 -0.02 (-0.19%)

As of 03:55 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Neon Therapeutics NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time